A5066286071- BRCA gene mutations in cancer
- Health Systems, Economic Evaluations, Quality of Life
- RNA Interference and Gene Delivery
- Pharmaceutical Economics and Policy
- Biomedical and Engineering Education
- Biotechnology and Related Fields
- Immunotherapy and Immune Responses
- Viral Infections and Immunology Research
- LGBTQ Health, Identity, and Policy
- Immune Response and Inflammation
- Economic and Financial Impacts of Cancer
- interferon and immune responses
- Science, Research, and Medicine
St. Michael's Hospital
2020-2024
University of Toronto
2023-2024
Wilfrid Laurier University
2023-2024
Unity Health Toronto
2023
Hereditary cancer syndromes (HCS) are one of the most common forms inherited diseases, accounting for up to 10% cancers. Breast and Ovarian Cancer Syndrome (HBOC) Lynch (LS) prevalent types HCS. Patients with HCS genetically more susceptible developing in their lifetime often require consistent, lifelong screening monitoring. Various facets patients' lives may be indirectly affected by diagnosis care. However, limited evidence describes range psychosocial lifestyle impacts following a...
Financial toxicity, also known as financial distress or burden, refers to the harmful effects caused by high costs of treatment on patients' well-being. Although toxicity is widely reported in cancer patients, there limited research its specific implications patients with hereditary syndromes (HCS), which account for approximately 10% all cases. This study aims explore direct and indirect associated two most common types HCS: Hereditary Breast Ovarian Cancer Syndrome (HBOC) Lynch (LS).
Hereditary cancer syndromes (HCS) account for approximately 10% of all cancers. Among HCS, Breast and Ovarian Cancer Syndrome (HBOC) Lynch (LS) are the most prevalent. In addition to medical burdens associated with genetic predisposition developing cancer, many individuals HCS concerned about stigmatization based on their diagnosis. This study aims describe experiences discrimination that may face care journey.
Hereditary cancer syndromes (HCS) account for 5-10% of all cancers. HCSs such as hereditary breast and ovarian syndrome (HBOC) or Lynch (LS) can increase one's lifetime risk by over 80%. HCS patients therefore require lifelong follow-up care, including screening appointments with a wide range specialists (eg, surgeons, gastroenterologists, oncologists). However, after receiving an diagnosis, are often left to navigate complex system care variable surveillance services programs across provinces.
Introduction: Hereditary cancer syndromes (HCS), such as Breast and Ovarian Cancer Syndrome (HBOC) Lynch (LS), represent approximately 10% of all cancers. Along with medical burdens associated the genetic risk developing cancer, many individuals face stigma discrimination. Genetic discrimination refers to negative treatment, unfair profiling or harm based on characteristics, manifesting “felt” (ostracization without discriminatory acts) “enacted” (experiencing acts). This study aimed...